Brought to you by 
Flagship seeds Sigilon with $23.5mm to develop Type I diabetes therapy
06 Apr 2018
Executive Summary
Flagship Pioneering launched Sigilon Therapeutics Inc. and seeded the company with $23.5mm. The start-up, armed with the research of its co-founders Daniel Anderson, PhD, and Robert Langer (both from MIT), is using an alginate-based polymeric capsule to encapsulate allogeneic cells that have been engineered into insulin-producing pancreatic beta cells. The company believes that its technology will avoid tissue scarring and immune responses that would other destroy implanted cells before they can be effective as a treatment for Type I diabetes.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Flagship seeds Sigilon with $23.5mm to develop Type I diabetes therapy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice